Background: Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta.
Objective: Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea.
Methods: Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months.
Results: The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness.
Conclusion: This is the first case series describing the successful application of imiquimod in the management of morphoea.